A5080460440- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Helicobacter pylori-related gastroenterology studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- Single-cell and spatial transcriptomics
- Bladder and Urothelial Cancer Treatments
- MicroRNA in disease regulation
- Colorectal and Anal Carcinomas
- Extracellular vesicles in disease
- Cancer-related gene regulation
- Cancer Cells and Metastasis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- PI3K/AKT/mTOR signaling in cancer
- Viral-associated cancers and disorders
- Circular RNAs in diseases
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Chemokine receptors and signaling
Samsung Medical Center
2017-2024
Sungkyunkwan University
2017-2024
Samsung (United Kingdom)
2023
Axcella Health (United States)
2023
University of California, Los Angeles
2021-2022
Zero to Three
2020
Samsung (South Korea)
2019
Chung-Ang University
2016
Chonnam National University
2005
Chemotherapy is ubiquitous in first-line treatment of advanced gastric cancer, yet responses are heterogeneous, and little known about mediators chemotherapy response. To move forward, an understanding the effects standard on tumor-immune microenvironment (TME) needed. Coupling whole-exome sequencing, bulk RNA single-cell transcriptomics from paired pretreatment on-treatment samples treatment-naïve patients with HER2-positive HER2-negative we define features associated response to...
Adding anti-programmed cell death protein 1 (anti-PD-1) to 5-fluorouracil (5-FU)/platinum improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To understand the effects of chemotherapy and immunotherapy, we conducted a phase II first-line trial (n = 47) sequentially adding pembrolizumab 5-FU/platinum GEA. Using serial biopsy primary tumor at baseline, after one cycle 5-FU/platinum, addition pembrolizumab, transcriptionally profiled 358,067 single cells identify evolving...
Objective: Panel-based sequencing is widely used to measure tumor mutational burden (TMB) in clinical trials and ready enter routine diagnostics. However, cut-off points distinguish "TMB-high" from "TMB-low" tumors are not consistent the implications of TMB predicting responses immune checkpoint blockade (ICB) gastric cancer clearly defined. We aimed assess whether associated with response immunotherapy examine its relation other biomarkers advanced cancer. Design: In total, 63 patients...
Background Tumor mutation burden (TMB) is an important biomarker to predict response anti-PD-L1 treatment across cancer types. TruSight Oncology 500 (TSO500) currently used globally as a routine assay for TMB. Methods Between 2019 and 2021, 1744 patients with received TSO500 part of real-world clinical practice at the Samsung Medical Center, 426 anti-PD-(L)1 treatment. Correlations between TMB outcomes were analyzed. Digital spatial profiling (DSP) was investigate tumor immune environment’s...
IntroductionProgrammed death-ligand 1 (PD-L1) can be overexpressed in tumours other than Epstein-Barr virus (EBV)-positive (EBV+) or microsatellite instability-high (MSI-H) gastric cancer (GC) subtypes. We aimed to determine the tumour immune microenvironment (TME) classification of GC better understand tumour–immune interactions and help patient selection for future immunotherapy with special reference MSI-H.MethodsImmunohistochemistry (IHC) PD-L1 CD8+ T cells three distinct subtypes (43...
Gastric cancer (GC) with peritoneal metastases and malignant ascites continues to have poor prognosis. Exosomes mediate intercellular communication during progression promote therapeutic resistance. Here, we report the significance of exosomes derived from (EXO Ascites ) in use modified as resources for therapy. EXO patients GC stimulated invasiveness angiogenesis an ex vivo three-dimensional autologous tumor spheroid microfluidic system. concentration increased invasiveness, blockade their...
Plasma cell-free DNA is being widely explored as a biomarker for clinical screening. Currently, methods are optimized the extraction and detection of double-stranded mononucleosomal ∼160bp in length. We introduce uscfDNA-seq, single-stranded next-generation sequencing pipeline, which bypasses previous limitations to reveal population ultrashort human plasma. This species has modal size 50nt distinctly separate from DNA. Treatment with specific nucleases suggests that primarily...
Abstract Purpose: Adding pembrolizumab to first-line fluoropyrimidine (5-FU)/platinum chemotherapy plus trastuzumab improves outcomes in advanced HER2+ gastroesophageal adenocarcinomas, but the benefit is largely confined dual and PD-L1+ patients. To assess contributions of components, we conducted a phase II trial evaluating 5-FU/platinum/trastuzumab added cycle 2 patients with metastatic disease. Patients Methods: Treatment-naïve cancer underwent baseline biopsy received single dose...
Abstract The tumor–stroma ratio (TSR) determined by pathologists is subject to intra- and inter-observer variability. We aimed develop a computational quantification method of TSR using deep learning-based virtual cytokeratin staining algorithms. Patients with 373 advanced (stage III [n = 171] IV 202]) gastric cancers were analyzed for TSR. Moderate agreement was observed, kappa value 0.623, between learning metrics (dTSR) visual measurement (vTSR) the area under curve receiver operating...
Abstract Background Recent advances in circulating cell-free DNA (cfDNA) analysis from biofluids have opened new avenues for liquid biopsy (LB). However, current cfDNA LB assays are limited by the availability of existing information on established genotypes associated with tumor tissues. Certain cancers present a list mutated biomarkers, and thus, nonmutated characteristics along alternative needed to broaden available targets cancer detection. Saliva is an intriguing accessible biofluid...
Abstract Copy number variations to chromosome 21 (HSA21) cause intellectual disability and Down Syndrome, but our understanding of the HSA21 genetic factors which contribute fetal brain development remains incomplete. Here, we focussed on neurodevelopmental functions for EURL (also known as C21ORF91 , Refseq Gene ID:54149), a protein-coding gene at centromeric boundary Syndrome Critical Region (DSCR) HSA21. We report that is expressed during human mouse cerebral cortex development,...
Inactivation of phosphatase and tensin homolog (PTEN) is caused by multiple mechanisms, loss PTEN activity related to the progression various cancers. In gastric cancer (GC), relationship between protein expression genetic alterations remains unclear. The effects microsatellite instability (MSI), Epstein–Barr virus (EBV), HER2 overexpression, PD-L1 on mutation have not been fully explored. We performed comprehensive panel tests with a cohort 322 tumor samples from patients advanced GC....
Programmed death-ligand 1 (PD-L1) expression in biopsies of gastric carcinoma may predict the results corresponding surgical specimens. We compared PD-L1 immunohistochemistry (IHC) 22C3 pharmDx paired biopsy and resection also characterized validity a new assay using digital image analysis. IHC with clone 73-10 was performed 224 cancer tissues (112 tissues) specimens were analyzed Leica Aperio Imagescope. For statistical analyses, area under receiver operating characteristic curve R package...
Abstract The use of four groups tumor immune microenvironments (TME) based on PD-L1 and tumor-infiltrating T lymphocytes (TIL) is a reliable biomarker for anti-PD-1/PD-L1 inhibitor therapy. We classified the TME in 241 gastric cancers which were subdivided according to 40 EBV+, 76 microsatellite instability-high (MSI-H), 125 EBV-/microsatellite-stable (MSS) subtypes by quantitative image analysis (QIA) correlated results with mRNA expression levels. mean ratio CD8 MSI-H, EBV−/MSS GCs...
Gastric cancer (GC) has the fifth highest incidence among cancers and is fourth leading cause of cancer-related death GC predominantly a higher number cases in certain ethnic groups such as Korean population. found at an early stage more treatable survival rate compared with late stage. However, diagnosis often delayed due to lack symptoms available screening programs United States. Extracellular RNA (exRNA) emerging paradigm; exRNAs have potential serve biomarkers panels aimed detection...
Abstract Gastric cancer (GC) is a heterogeneous disease, so molecular classification important for selecting the most appropriate treatment strategies GC patients. To be applicable in clinic, there an urgent need platform that will allow screening real-life archival tissue specimens. For this purpose, we performed RNA sequencing of 50 samples from our Asian Cancer Research Group (ACRG) cohort to reproduce subtypes using tissues with different platforms. We filtered out genes...
<div>Abstract<p>Adding anti–programmed cell death protein 1 (anti–PD-1) to 5-fluorouracil (5-FU)/platinum improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To understand the effects of chemotherapy and immunotherapy, we conducted a phase II first-line trial (<i>n</i> = 47) sequentially adding pembrolizumab 5-FU/platinum GEA. Using serial biopsy primary tumor at baseline, after one cycle 5-FU/platinum, addition pembrolizumab, transcriptionally...
Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is widely used to predict the clinical responses immune checkpoint inhibitors (ICIs). However, PD-L1 IHC suffers from complexity of multiple testing platforms and different cutoff values caused by current one drug-one diagnostic test co-development approach for ICIs. We aimed whether (CD274) mRNA expression levels measured using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) can represent ICI. The...
Abstract Automatic quantification of biomarkers such as tumor‐infiltrating lymphocytes and PD‐L1 is one the most studied topics in digital pathology image analysis (DIA). However, direct comparison between DIA a whole‐slide (WSI) that regions interest (ROIs) chosen by pathologists has not been performed. In this study, we aimed to compare prognostic value tumor microenvironment markers CD8 PD‐L1, measured WSIs ROIs. We selected 153 primary gastric cancer tissues stained them with PD‐L1. All...
CDH1 mutation is the most frequent genetic alteration in hereditary diffuse gastric cancer (GC) and early onset GC patients. However, incidence of mutations sporadic with or without family history has not been studied. This retrospective study includes a total 993 Korean patients primary advanced who underwent surgery received palliative chemotherapy. Targeted deep sequencing was performed all cases searched survival analysis. We found alterations 146 (14.7 %) 8 were germline (0.8 %). Out...